vrna
VRNA67.570USD
+0.039+0.06%
종가 05/13, 16:00（ET）시세는 15분 지연됩니다
46.02B시가총액
손실P/E TTM
자세한 내용은 Verona Pharma PLC 회사
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
회사 정보
회사 코드VRNA
회사 이름Verona Pharma PLC
상장일Mar 30, 2005
설립일2005
CEODr. David S. Zaccardelli
직원 수209
유형Depository Receipt
회계 연도 종료Mar 30
주소Riverside
도시LONDON
증권 거래소NASDAQ Global Market Consolidated
국가United Kingdom
우편 번호SE1 2RE
전화442032834200
웹사이트https://www.veronapharma.com/
회사 코드VRNA
상장일Mar 30, 2005
설립일2005
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.27M
-3.32%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.35M
-3.60%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Director
Non-Executive Director
--
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Director
Non-Executive Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.27M
-3.32%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.35M
-3.60%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주주
업데이트 시간: Fri, May 9
업데이트 시간: Fri, May 9
주주 통계
유형
주주 통계
주주
비율
Zaccardelli (David S)
13.23%
Hahn (Mark W)
12.16%
Perceptive Advisors LLC
7.51%
New Enterprise Associates (NEA)
4.80%
Frazier Life Sciences Management, L.P.
3.97%
Other
58.32%
주주 통계
주주
비율
Zaccardelli (David S)
13.23%
Hahn (Mark W)
12.16%
Perceptive Advisors LLC
7.51%
New Enterprise Associates (NEA)
4.80%
Frazier Life Sciences Management, L.P.
3.97%
Other
58.32%
유형
주주
비율
Individual Investor
34.54%
Investment Advisor/Hedge Fund
21.57%
Hedge Fund
21.47%
Investment Advisor
16.02%
Private Equity
11.73%
Venture Capital
6.76%
Research Firm
3.33%
Family Office
1.04%
Bank and Trust
0.28%
기관 주식 보유
업데이트 시간: Tue, Mar 4
업데이트 시간: Tue, Mar 4
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
362
99.25M
116.64%
+16.32M
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
2022Q4
162
65.88M
87.36%
-542.66K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Zaccardelli (David S)
11.51M
13.55%
+10.91M
+1.80K%
Mar 01, 2025
Hahn (Mark W)
10.60M
12.48%
+10.34M
+4.02K%
Mar 01, 2025
Perceptive Advisors LLC
6.39M
7.52%
+76.17K
+1.21%
Dec 31, 2024
New Enterprise Associates (NEA)
4.08M
4.81%
-1.50M
-26.86%
Jan 16, 2025
Frazier Life Sciences Management, L.P.
3.38M
3.98%
--
--
Dec 31, 2024
Ali (Behbahani)
3.19M
3.76%
+3.19M
--
Jan 16, 2025
Eventide Asset Management, LLC
3.13M
3.69%
+706.28K
+29.11%
Dec 31, 2024
Maverick Capital, Ltd.
3.13M
3.68%
-1.09M
-25.79%
Dec 31, 2024
Wellington Management Company, LLP
3.03M
3.56%
+1.15M
+61.03%
Dec 31, 2024
Summit Partners Public Asset Management, LLC
1.90M
2.24%
+1.90M
--
Dec 31, 2024
더 보기
관련 ETF
업데이트 시간: Tue, May 6
업데이트 시간: Tue, May 6
이름
비율
AdvisorShares Dorsey Wright ADR ETF
6.2%
ALPS Medical Breakthroughs ETF
4.06%
First Trust IPOX Europe Equity Opportunities ETF
1.46%
Invesco Nasdaq Biotechnology ETF
0.52%
ProShares Ultra Nasdaq Biotechnology
0.5%
iShares Biotechnology ETF
0.3%
Goldman Sachs Innovate Equity ETF
0.14%
Eventide US Market ETF
0.11%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Long/Short Equity ETF
0%
더 보기
AdvisorShares Dorsey Wright ADR ETF
비율6.2%
ALPS Medical Breakthroughs ETF
비율4.06%
First Trust IPOX Europe Equity Opportunities ETF
비율1.46%
Invesco Nasdaq Biotechnology ETF
비율0.52%
ProShares Ultra Nasdaq Biotechnology
비율0.5%
iShares Biotechnology ETF
비율0.3%
Goldman Sachs Innovate Equity ETF
비율0.14%
Eventide US Market ETF
비율0.11%
Fidelity Nasdaq Composite Index ETF
비율0.01%
First Trust Long/Short Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음